DATA GRAPHICS | Data Byte
TSLP mAbs for asthma behind Tezspire
At least eight mAbs in development; two also hit IL-13
January 10, 2024 2:30 AM UTC
GSK’s acquistion of Aiolos marks enthusiasm for differentiated TLSP mAbs in the asthma arena.
Just 11 weeks after Aiolos Bio Inc. announced a $245 million series A round to support development of its in-licensed asset for asthma, the start-up’s leadership team has negotiated a $1 billion sale to GSK plc (LSE:GSK; NYSE:GSK)...
BCIQ Company Profiles